YS 110

Drug Profile

YS 110

Alternative Names: Humanized anti-CD26 monoclonal antibody - Kissei; YS110; YSCMA

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ys Therapeutics
  • Developer Kissei Pharmaceutical; Ys Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Renal cell carcinoma

Most Recent Events

  • 01 Jun 2017 Phase-I/II clinical trials in Mesothelioma (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in Japan (IV) (NCT03177668)
  • 08 Jun 2016 Kissei Pharmaceutical and the Japan Agency for Medical Research and Development are collaborating to develop YS 110 in Japan for Mesothelioma (before June 2016; Kissei Pharmaceutical pipeline, June 2016)
  • 02 Jun 2015 Y's Therapeutics completes a phase I trial in Mesothelioma and Renal cell carcinoma in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top